Cytotoxic/antiproliferative effects of new [1,2,4]triazolo[4,3-c] quinazolines in tumor cell lines HeLa and B16

Neoplasma

Volumn 53, Issue 4, 2006, Pages 291-300

  Jantova S ^a   Letasiva S ^a   Ovadekova R ^a   Muckova M ^b  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^b Drug Research Institute   (Slovakia)

Author keywords

B16 and Hela cells; Cytotoxic antiproliferative effects; DNA damage; Necrosis; 1,2,4 triazolo 4,3 c quinazolines

Indexed keywords

3 (5 NITRO 2 THIENYL) 9 CHLORO 5 MORPHOLIN 4 YL[1,2,4]TRIAZOLO[4,3 C]QUINAZOLINE; DNA FRAGMENT; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; [1,2,4]TRIAZOLO[4,3, C]QUINAZOLINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA MODIFICATION; DRUG DNA INTERACTION; DRUG EFFECT; ELECTRODE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MELANOMA; MOUSE; NECROSIS; NONHUMAN; TUMOR CELL LINE;

EID: 33746269697     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. WISELOGE FW. Survey of antimalarig drugs 1941-1945. In: Armarego WLF, editor. Advances in heterocyclic chemistry. Vol 1. New York: Academic Press, 1963: 296-304.
2. ABDEL-RAHMAN TM. Synthesis of some new biologically active 2,3-disubstituted quinazolin-4-ones. Boll Chim Farm 1998; 137: 43-47.
3. FARGHALY AM, CHAABAN I, KHALIL MA, BEKHIT AA. Non-steroidal antiinflammatory agents. Synthesis of novel 2-pyrazolyl-4(3)-quinazolinones. Arch Pharmacol 1990; 323: 833-836.
4. POMARNACKA E, ANGIELSKI S, HOPPE A. Derivatives of 4-chloro-5-sulfanoyl- benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2-b]quinazoline and 1-benzoylpyrazole derivatives. Acta Polon Pharm 1984; 41: 141-151.
5. KORNET MJ. Synthesis and anticonvulsant activity of 3-alkyl-3,4-dihydro- 2(1H)-quinazolinones, J Heterocyclic Chem 1992; 29: 103-105.
6. SHIMOYAMA M, OGINO K, TANAKA Y, IKEDA T, HISATOME I. Hemodynamic basic for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999; 3: 609-615.
7. SORENSON CHM, BARRY MA, EASTMAN A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-754.
8. NAITHANI PK, PALIT G, SRIVASTAVA VK, SHANKER K. 2,3-disubstituted quinazolinones and their antiparkinsonian activity. Ind J Chem Sect B, Org Chem Incl Med Chem 1989; 28: 745-750.
9. LORIGA M, VITALE G, PAGLIETTI G. Quinoxaline chemistry. Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid (CB3717) and its precursors. Synthesis and evaluation of in vitro anticancer activity. Farmaco 1998; 53: 139-149.
10. SOTELO-MUNDO RR, CIESLA J, DZÍK JM, RODE W, MALEY F et al. Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. Biochemistry 1990; 38: 087-1094.
11. JANTOVÁ S, URBANČÍKOVÁ M, MALIAR T, MIKULÁŠOVÁ M, RAUKOP et al. Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton. Neoplasma 2001; 1: 52-60.
12. TONKINSON JL, MARDER P, ANDIS SL, SHULTZ RM, GOSSETT LS et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostatis. Cancer Chemother Pharmacol 1997; 39: 521-531.
13. RANSON M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004; 90: 2250-2255.
14. POLSHAKOV VI, BIRDSAlL B, FRENKIEL TA, GARGARO AR, FEENEY J. Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate. Protein Sci 1999; 8: 467-481.
15. BOS M, MENDELSOHN J, KIM YM, ALBANELL J, FRY DW, BASELGA J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3: 2099-2106.
16. YAMAGISHIM, YAMADA Y, OZAKIK, ASA M, SHIMIZU R et al. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4-4,-(1H)quinazoline-2,2,5(H)-triones as aldose reductase inhibitors. J Med Chem 1992; 35: 2085-2094.
17. TAKEMURA Y, JACKMAN A. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anti-Cancer Drugs 1997; 8: 3-16.
18. HAMEL E, LIN CM, PLOWMANI J, WANG HK, LEE KH, PAULL KD. Antitumour 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin. Biochem Pharmacol 1996; 51: 53-59.
19. MODJTAHEDI H, AFFLECK K, STUBBERFIELD C, DEAN C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998; 13: 335-342.
20. HOLDEN SA, TEICHER BA, ROBINSON MF, NORTHEY D, ROSOWSKY A. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother 1995; 36: 165-171.
21. KAYE SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78: 1-7.
22. ŠPIRKOVÁ K, STANKOVSKÝ Š. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c]quinazolines. Collect Czech Chem Commun 1991; 56: 1719-1724.
23. ŠPIRKOVÁ K, STANKOVSKÝ Š, HORŇÁČEK J. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-e]quinazolines and their [1,5-c]isomers. Chem Paper 1993; 6: 382-385.
24. JANTOVÁ S, OVÁDEKOVÁ R, LETAŠIOVÁ S, ŠPIRKOVÁ K, STANKOVSKÝ S. Antimicrobial activity of some substituted triazoloquinazolines. Folia Microbiol 2005; 50: 90-94.
25. LABUDA J, BUČKOVÁ M, JANTOVÁ S, ŠTEPÁ NEK I, SURUGIUI et al. Modified screen-printed electrodes for the investigation of the interaction of non-electroactive quinazoline derivatives with DNA. J Anal Chem 2000; 367: 364-368.
26. De-LOS-SANTOS-ALVAREZI P, LOBO-CASTAŇÓN MJ, MIRANDA-ORDIERES J, TUŇÓN-BLANCO P. Electrochemistry of Nucleic Acids at Solid Electrodes and Its Applications. Electroanalysis 2004; 16: 1193-1204.
27. JANTOVÁ S, THEISZOVÁ M, MIKULÁŠOVÁ M. Cytotoxic and genotoxic effects of some substituted tetrazolo[1,5-c] quinazolines. Neoplasma 2004; 6: 437-442.
28. JANTOVÁ S, ČIPÁK E, ČERŇÁ KOVÁ M, KOŠŤÁLOVÁ D. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharmacol 2003; 55: 1143-1149.
29. CIARDIELLO F, CAPUTO R, BIANCO R, DAMIANO V, POMATICO G et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
30. FAUST RA, TAWFIC S, DAVIS AT, AHMED K. Apoptosis and growth inhibition of head and neck tumor cell line induced sby epidermal growth factor receptor tyrosine kinase inhibitor. Oral Oncol 1999; 35: 290-295.
31. KARNES WE JR, WELLER SG, ADJEI PN, KOTTKE TJ, GLENN KS et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cell. Gastroenterology 1998; 114: 930-939.
32. KIMOTO T, HINO K, KOYA-MIYATA S, YAMAMOTO Y, TAKEUCHI M et al. Cell differentiation and apoptosi of monocytic and promyeloytic leukemia cells (U-937 and HL-60) by tryptanthin, an active ingredient of Polygonum tinctorium Lour. Pathol Int 2001; 51: 315-325.
33. NARLA RK, LIU XP, MYERS DE, UCKUN FM. 4-(3α-bromo-4'hydroxylphenyl) -amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res 1998; 4: 1405-1414.
34. PARK JK, LEE SH, KANG JH, NISHIO K, SAIJO N, KUH HJ. Synergistic interaction between gefitinib (Iressa, ZD1839) and oarlitaxel against human gastric carcinoma cells. Anticancer Drugs 2004; 8: 809-818.
35. SHINTANI S, LI C, MIHARA M, YANO J, TERAKADLO N et al. Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Onco 2004; 1: 43-51.
36. JAISWAL M, LIPINSKI LJ, BOHR VA, MAZUR SJ. Efficient in vitro repair of 7-hydro-8-oxodeoxyguanosine by human cell extracts: involvement of multiple pathways. Nucleic Acids Res 1998; 26: 2184-2191.
37. CHANG GC, HSU SL, TSAI JR, LIANG FP, LIN SY et al. Molecular mechanism of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 2004; 7: 1453-1464.
38. SANDSTROM M, JOHANSSON M, ANDERSSON U, BERGH A, BERGENHEIM AT, HENRIKSSON R. The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model. Br J Cancer 2004; 6: 1174-1180.
39. TRACY S, MUKOHARA T, HANSEN M, MEYERSON M, JOHNSON BE, JANNE PA. Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 20: 7241-7244.
40. GRUNWALD V, HIDALGO M. Development of the epidermal growth factor receptor inhibitor tarceva (OSI-774). Edv Exp Med Biol 2003; 532: 235-246.
41. AUSTIN PF, COOK BL, NIEDERHOFF RA, MANSON SR, COPLEN DE WEINTRAUB SJ. Inhibition of mitogenic signaling and induction of apoptosis inhuman bladder smooth muscle cells treated with doxazosin. J Urol 2004; 4: 1662-1665.
42. YANG Z, BAGHERI-YARMAND R, WANG RA, ADAM L, PAPADIMITRAKOPOULOU VV et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839(Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 2004; 10: 658-667.
43. JANTOVÁ S, LETAŠIOVÁ S, REPICKÝ A, OVÁDEKOVÁ R, LAKATOŠ B. The effect of 3-(5-nitro-2-thienyl- 9-chloro-5-morpholino-4-yl [1,2,4]triazolo[4, 3-c]quinazoline on cell growth, induction of DNA fragmentation and activity of caspase 3 in murine L1210 cells and fibroblast NIH-3T3 cells. Cell Biochem Funct 2005; 23: in press.
44. YANG IW, CHOU CC, YUNG BY. Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Naunyn-Schmiedeberg's Arch Pharm 1996; 2: 102-108.
45. GOOSSENS JF, BOUEY-BENCTEUX E, HOUSSIN R, HENICHART JP, COLSON P et al. DNA interaction of the tyrosine protein kinase inhibitor PD153035 and its N-mathyl analogue. Biochemistry 2001; 15: 4663-4671.
46. MALECKIN, CARATO P, BENOIT R, GOOSSENS JF, HOUSSIN R et al. Synthesis of condensed quinolines and quinazolines as DNA ligands. Bioorg Med Chem 2004; 12: 641-647.
47. OVÁDEKOVÁ R, JANTOVÁ S, LABUDA J. Detection of the effective DNA protection by quinazolines using a DNA-based electrochemical biosensor. Analytical Letters 2005; 38: 2625-2638.